Skip to content
Austin Top 50
Author:
PRF Technologies Ltd.
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
May 26, 2026
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
April 28, 2026
←
Previous Page
1
2